Baker Avenue Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Baker Avenue Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$340K	Buy	1,800 +367	+26%	+$64.1K	0.01%	561
2025 Q4	$244K	Buy	+1,433	New	+$220K	0.01%	560
2023 Q4	–	Sell	-10	Closed	-$1.29K	–	937
2023 Q3	$1.29K	Hold	10	–	–	﹤0.01%	1226
2023 Q2	$1.24K	Hold	10	–	–	﹤0.01%	1109
2023 Q1	$1.46K	Sell	10 -12	-55%	-$1.77K	﹤0.01%	1067
2022 Q4	$3.5K	Buy	+22	New	+$3.22K	﹤0.01%	861
2020 Q1	–	Sell	-1,500	Closed	-$223K	–	231
2019 Q4	$223K	Buy	+1,500	New	+$204K	0.02%	245
2015 Q2	–	Sell	-1,440	Closed	-$249K	–	259
2015 Q1	$249K	Sell	1,440 -60	-4%	-$10.3K	0.03%	202
2014 Q4	$246K	Buy	+1,500	New	+$249K	0.03%	232
2014 Q1	–	Sell	-1,700	Closed	-$215K	–	236
2013 Q4	$215K	Sell	1,700 -1,600	-48%	-$166K	0.04%	227
2013 Q3	$304K	Buy	+3,300	New	+$266K	0.06%	159

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Baker Avenue Asset Management's JAZZ Position: Q1 2026 in Review

Baker Avenue Asset Management increased its Jazz Pharmaceuticals (JAZZ) stake by 26% in Q1 2026, buying an estimated $64.1K and bringing the position to 1,800 shares worth $340K. The position accounts for 0.01% of the portfolio, ranked #561.

Baker Avenue Asset Management first reported a position in JAZZ in Q3 2013 and has held it in 11 quarters since. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

Baker Avenue Asset Management held 1,800 shares of Jazz Pharmaceuticals worth $340K as of Q1 2026.
Baker Avenue Asset Management bought 367 Jazz Pharmaceuticals shares in Q1 2026, an estimated $64.1K.
Jazz Pharmaceuticals made up 0.01% of Baker Avenue Asset Management's portfolio in Q1 2026, its #561 holding.
Baker Avenue Asset Management first reported a position in Jazz Pharmaceuticals in Q3 2013 and has held it in 11 quarters since.
570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Baker Avenue Asset Management's 13F filing for Q1 2026, filed 12 May 2026.